FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059642757> ?p ?o ?g. }

• W2059642757 endingPage "103" @default.
• W2059642757 startingPage "94" @default.
• W2059642757 abstract "To compare the mechanism of action of raloxifene and gosereline induced shrinkage of leiomyomas via estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically.Thirty-two premenopausal women affected by uterine leiomyomas were randomized into two equal groups. Group A was treated with gosereline (3.6 mg subcutaneous injection monthly) and group B was treated with raloxifene (60 mg daily per os) for 3 months before undergoing surgery. At entry and at the end of the treatment the leiomyoma volume was measured ultrasonografically and the volume change was calculated. Immunohistochemical detection of estrogen receptor (ER), progesterone receptor (PR), bcl-2 and p53 were performed on leiomyoma tissue samples from group A, group B and the matched-control group. H-scores for ER, PR, bcl-2 and p53 were calculated. The mean volume changes of leiomyomas and immunohistochemical H-score differences of ER, PR, bcl-2 and p53 were compared between groups.The leiomyoma volume decreased significantly after treatment in gosereline group from baseline of 65 cm(3) to 35 cm(3), and in raloxifene group from 68 cm(3) to 50 cm(3), p<0.05. The difference between the before and after treatment leiomyoma volumes between the two treatments was not statistically significant. H-score of ER expression was significantly lower in gosereline group compared to control group (54.4 versus 113.2, p = 0.001), whereas H-score of PR expression was significantly lower with both gosereline and raloxifene groups compared to control group (64.8 for gosereline versus 94.6 for control, 73.6 for raloxifene versus 94.6 for control, p = 0.001). The bcl-2 expression was higher in both gosereline and raloxifene groups compared to control group (173.7 for gosereline versus 94.7 for control, 179.7 for raloxifene versus 94.7 for control, p = 0.001). The p53 expression was only lower with gosereline than the control group (169.4 versus 205.6, p = 0.001), whereas there was no significant change between the raloxifene group and the control group (201.9 versus 205.6) (p>0.05).Raloxifene was as effective as gosereline in reducing leiomyoma volumes. Decreased PR expression may be a mechanism for tumor growth reduction in raloxifene treatment. In both treatment modalities, the mechanism of shrinkage of leiomyomas could not be increased apoptosis mediated by bcl-2 and p53 expression and should be investigated by further studies." @default.
• W2059642757 created "2016-06-24" @default.
• W2059642757 creator A5001298052 @default.
• W2059642757 creator A5026477370 @default.
• W2059642757 creator A5048684706 @default.
• W2059642757 creator A5052135984 @default.
• W2059642757 creator A5052397827 @default.
• W2059642757 creator A5068655041 @default.
• W2059642757 creator A5082867650 @default.
• W2059642757 date "2007-11-01" @default.
• W2059642757 modified "2023-10-06" @default.
• W2059642757 title "A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women" @default.
• W2059642757 cites W1973729154 @default.
• W2059642757 cites W1984365059 @default.
• W2059642757 cites W1985113566 @default.
• W2059642757 cites W1986474915 @default.
• W2059642757 cites W1986507544 @default.
• W2059642757 cites W1992102887 @default.
• W2059642757 cites W2003275951 @default.
• W2059642757 cites W2008039212 @default.
• W2059642757 cites W2014994159 @default.
• W2059642757 cites W2027839941 @default.
• W2059642757 cites W2031336834 @default.
• W2059642757 cites W2049555849 @default.
• W2059642757 cites W2058591356 @default.
• W2059642757 cites W2064600192 @default.
• W2059642757 cites W2074196470 @default.
• W2059642757 cites W2078632549 @default.
• W2059642757 cites W2086189048 @default.
• W2059642757 cites W2088632210 @default.
• W2059642757 cites W2095354180 @default.
• W2059642757 cites W2104217934 @default.
• W2059642757 cites W2110117792 @default.
• W2059642757 cites W2111464700 @default.
• W2059642757 cites W2111510880 @default.
• W2059642757 cites W2112629831 @default.
• W2059642757 cites W2118574762 @default.
• W2059642757 cites W2169267869 @default.
• W2059642757 cites W2407801709 @default.
• W2059642757 cites W2413268561 @default.
• W2059642757 cites W4233554205 @default.
• W2059642757 cites W4236319195 @default.
• W2059642757 cites W4240750899 @default.
• W2059642757 cites W4244064113 @default.
• W2059642757 cites W4245395118 @default.
• W2059642757 cites W4245610963 @default.
• W2059642757 cites W4246691084 @default.
• W2059642757 cites W4249983286 @default.
• W2059642757 cites W4250606730 @default.
• W2059642757 cites W4252324965 @default.
• W2059642757 doi "https://doi.org/10.1016/j.ejogrb.2006.07.042" @default.
• W2059642757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16973256" @default.
• W2059642757 hasPublicationYear "2007" @default.
• W2059642757 type Work @default.
• W2059642757 sameAs 2059642757 @default.
• W2059642757 citedByCount "12" @default.
• W2059642757 countsByYear W20596427572014 @default.
• W2059642757 countsByYear W20596427572016 @default.
• W2059642757 countsByYear W20596427572017 @default.
• W2059642757 countsByYear W20596427572020 @default.
• W2059642757 countsByYear W20596427572023 @default.
• W2059642757 crossrefType "journal-article" @default.
• W2059642757 hasAuthorship W2059642757A5001298052 @default.
• W2059642757 hasAuthorship W2059642757A5026477370 @default.
• W2059642757 hasAuthorship W2059642757A5048684706 @default.
• W2059642757 hasAuthorship W2059642757A5052135984 @default.
• W2059642757 hasAuthorship W2059642757A5052397827 @default.
• W2059642757 hasAuthorship W2059642757A5068655041 @default.
• W2059642757 hasAuthorship W2059642757A5082867650 @default.
• W2059642757 hasConcept C121608353 @default.
• W2059642757 hasConcept C126322002 @default.
• W2059642757 hasConcept C126894567 @default.
• W2059642757 hasConcept C134018914 @default.
• W2059642757 hasConcept C142724271 @default.
• W2059642757 hasConcept C170493617 @default.
• W2059642757 hasConcept C204232928 @default.
• W2059642757 hasConcept C2777164284 @default.
• W2059642757 hasConcept C2777795800 @default.
• W2059642757 hasConcept C2777944059 @default.
• W2059642757 hasConcept C2779066055 @default.
• W2059642757 hasConcept C2779889926 @default.
• W2059642757 hasConcept C3017725331 @default.
• W2059642757 hasConcept C530470458 @default.
• W2059642757 hasConcept C71924100 @default.
• W2059642757 hasConcept C84606932 @default.
• W2059642757 hasConcept C98717036 @default.
• W2059642757 hasConceptScore W2059642757C121608353 @default.
• W2059642757 hasConceptScore W2059642757C126322002 @default.
• W2059642757 hasConceptScore W2059642757C126894567 @default.
• W2059642757 hasConceptScore W2059642757C134018914 @default.
• W2059642757 hasConceptScore W2059642757C142724271 @default.
• W2059642757 hasConceptScore W2059642757C170493617 @default.
• W2059642757 hasConceptScore W2059642757C204232928 @default.
• W2059642757 hasConceptScore W2059642757C2777164284 @default.
• W2059642757 hasConceptScore W2059642757C2777795800 @default.
• W2059642757 hasConceptScore W2059642757C2777944059 @default.
• W2059642757 hasConceptScore W2059642757C2779066055 @default.
• W2059642757 hasConceptScore W2059642757C2779889926 @default.

• next